Valuing a Technology Before There’s a Company
Pre-Revenue Valuation in Healthcare Innovation
The learning framework
The friendly valuation that set the whole schedule
An inventor raises a first round from people who believe in her. The valuation is low, because a low number is easy to agree on, it closes quickly, and it feels modest rather than greedy. She tells herself the percentage does not matter yet, because the company is worth almost nothing today and the value is all ahead. The value does arrive. So do three more rounds, each priced against the baseline the first one set. By the time the company is worth what she always believed it would be, the founding position has been anchored low from the start and compounded down from there. The technology performed. The first number, chosen for how it felt rather than for what it committed her to, did most of the damage before the science ever had a chance to. The opposite error ends the same way. A valuation set too high to look impressive invites a later round priced below it, and a down round resets everyone, founder included, from a lower floor than an honest number would have.
Why pre-revenue valuation is treated as guesswork
The tools most people associate with valuation do not work here. There are no cash flows to discount, no earnings to multiply, and few clean comparables, because the closest deals differ in stage, indication, and structure. So founders conclude the number is arbitrary and defer to whoever is writing the check, on the theory that the investor must know better. The investor does not know better. They have a method, a set of comparables, and a required return, and they are using all three to anchor a negotiation. Pre-revenue valuation is uncertain, but it is not arbitrary. Risk-adjusted net present value, comparable transactions, and the venture capital method each produce a defensible range from probability, from recent deals, and from an expected exit worked backward. The error is not that the number is hard to calculate. The error is arriving without one of your own.
A number you set rather than one you receive
Healthcare innovators who complete this evolution arrive at the table with a valuation range they built, a method behind it, and a narrative that defends it. They know how the probability of regulatory and clinical success feeds the risk adjustment, so the pathway they chose is visible in the number. They can read which lens they are being valued through, because an angel, a venture fund, a strategic acquirer, and a licensor each value the same asset differently. They still expect to negotiate. They now negotiate against a number of their own rather than accepting the only one in the room.
By the end of this evolution, you will be able to:
Choose a valuation method that fits your stage
Understand when risk-adjusted NPV, comparable transactions, the venture capital method, and earlier-stage scorecard approaches each apply. Recognize why the method that suits a preclinical asset is not the one that suits a device approaching a pivotal study.
Build a risk-adjusted NPV
Probability-weight future cash flows by technical, regulatory, and commercial success. Understand how the regulatory pathway you chose sets those probabilities, and therefore how directly the pathway decision drives the number.
Read comparable transactions
Find recent medtech and biotech deals and adjust them for stage, indication, and structure. Understand why a headline deal figure is not the figure you can claim, and what has to be normalized before a comparable means anything.
Treat valuation as a negotiated anchor rather than a fact
Understand that a pre-revenue number is a claim you must defend, not a value you can prove. Whoever brings the most defensible claim sets the anchor the negotiation moves around.
See how today's valuation compounds into your exit position
Trace how the number set at the first priced round prices every round after it. Understand why a valuation set too low over-dilutes the founder and one set too high invites a down round, and why the valuation path is an ownership path.
Value the same asset through different eyes
Compare what an angel, a venture fund, a strategic acquirer, and a licensor each optimize for. Understand why the same technology is worth different amounts to each, and what to emphasize depending on whose lens you are being valued through.
Defend a number to the person across the table
Assemble the method, the comparables, and the narrative into a valuation you can hold in a room with an investor or an acquirer. Understand which parts of a valuation are negotiable, which are structural, and where a challenge to your number is really a challenge to your assumptions.
Why this matters
Recommended for
Healthcare innovators navigating:
Faculty who understand the process move through it faster.
Academic medical centers, research universities, and health systems sponsor cohorts so that inventors arrive at the office of technology transfer prepared: complete disclosures, clean assignment records, and realistic expectations about pathway and timeline. Cohort training is available for faculty, residents, and research staff, with CME.
Learn more about institutional cohorts →How to get started
Your path to becoming a Certified Professional Entrepreneur
Reserve your seat
Your deposit reserves a place in the cohort. Twenty seats. No application, no admissions committee, no waiting on a decision.
Begin the evolutions
Structured online learning you work through on your own schedule. Lectures run under fifteen minutes. Each evolution carries reading, supporting material, working tools, and case studies drawn from real transactions.
Join the live sessions
Live discussion sessions on Zoom, facilitated by Chris and Christos. Not recorded. This is where the material meets your actual situation, and where the cohort becomes a network.
Continue your structural training
Answers that help you decide with confidence
A pre-revenue valuation is a claim, not a calculation.